PTC Therapeutics

Historical price data

PTC Therapeutics is a patient-centric, commercial-stage biopharma focused on discovering, developing, and commercializing clinically differentiated medicines for rare diseases. The company has achieved multiple regulatory firsts, including the first global treatment for Duchenne muscular dystrophy (Translarna), the first brain-infused gene therapy (Upstaza), and the first small molecule splicing modifier for spinal muscular atrophy (Evrysdi). Its strategy leverages two proprietary scientific platforms—Splicing and Inflammation & Ferroptosis—to build a diversified pipeline, supported by a global commercial infrastructure aimed at sustainable growth and expanding patient access.

PTC operates two proprietary platforms: a Splicing Platform for modulating RNA splicing with small molecules to control protein production, and an Inflammation & Ferroptosis Platform targeting oxidative stress and iron-dependent cell death pathways.